We show dose-escalating concentrations of a dominant TNFR2 antagonistic antibody killed TNFR2+ SS tumor cells and thus restored CD26− subpopulations of lymphocyte cell numbers to normal. The gene discussed is TNFRSF1B; the disease is neoplasm.